WO2003063763A2 - Essais a mediation par complement pour des procedes in vivo et in vitro - Google Patents

Essais a mediation par complement pour des procedes in vivo et in vitro Download PDF

Info

Publication number
WO2003063763A2
WO2003063763A2 PCT/US2002/016302 US0216302W WO03063763A2 WO 2003063763 A2 WO2003063763 A2 WO 2003063763A2 US 0216302 W US0216302 W US 0216302W WO 03063763 A2 WO03063763 A2 WO 03063763A2
Authority
WO
WIPO (PCT)
Prior art keywords
complement
antibody
prp
prion
assay
Prior art date
Application number
PCT/US2002/016302
Other languages
English (en)
Other versions
WO2003063763A3 (fr
Inventor
Elliot R. Ramberg
Original Assignee
Cygene, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cygene, Inc. filed Critical Cygene, Inc.
Priority to EP02806678A priority Critical patent/EP1506314A4/fr
Priority to JP2003563459A priority patent/JP2005516198A/ja
Priority to AU2002365902A priority patent/AU2002365902A1/en
Priority to CA002447892A priority patent/CA2447892A1/fr
Publication of WO2003063763A2 publication Critical patent/WO2003063763A2/fr
Publication of WO2003063763A3 publication Critical patent/WO2003063763A3/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/18—Erythrocytes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells

Definitions

  • the present invention is directed to methods and compositions for detecting pathological conditions.
  • the invention comprises methods and compositions using biological factors, such as complement components, for detecting pathological conditions.
  • Diagnostics has traversed a broad range of disciplines from an initial foothold in serologic diagnostics to DNA molecular diagnostics, such as those using PCR. Problems with many current diagnostic technologies include the inability to directly detect species specific mRNA and proteins, and many also lack specificity and sensitivity.
  • PrP sc Creutzfeld- Jakob disease (CJD) of humans and bovine spongiform encephalitis (BSE) and scrapie of animals are neurodegenerative diseases caused by prion proteins.
  • the infectious prion is an abnormal disease-producing isoform of the normal prion protein (PrP) called PrP sc .
  • PrP sc normal prion protein
  • Brain damage in prion disease occurs when abnormal prion protein molecules, as a consequence of ingestion gain entry to the brain and cause normal PrPs to take on the e disease causing PrP form.
  • the target may be nucleic acid, such as DNA and RNA, cellular, or protein, in nature.
  • these methods and compositions comprise diagnostic technology that supports high levels of specificity and sensitivity in testing procedures.
  • Preferred methods and compositions comprise diagnostic tests that are configured for early detection of the pathologic agent or other target in the sample by examining the DNA, RNA, cell, or soluble protein in solution, to detect the pathologic target earlier in the infection time-course.
  • the present invention is directed to methods and compositions for detecting pathological conditions.
  • the invention comprises methods and compositions using biological factors, such as complement components, for detecting pathological conditions.
  • biological factors such as complement components
  • assays for non-specific target elimination that allow for detection of low copy number targets in a large field of nontarget material.
  • Such assays comprise methods comprising CMSA and MACMSA, which preferably comprise detection of complement proteins and components.
  • the assays of the present invention can be used for detection of changes in cellular molecules or nucleic acids that are part of disease states or infections, or can be used for detection of molecules in the environment.
  • the methods and compositions of the present invention comprise detection of nucleic acid and other molecular targets, but the methods and compositions of the present invention comprise diagnostics at supramolecular levels to confirm the presence of the pathologic or other cellular targets in tissues.
  • the present invention comprises the analysis of only the cell subset of interest in a very large cell specimen and has the ability to compartmentalize and assay each cell component for the analyte of interest.
  • Other embodiments comprise target analyte sorting and separation from non-specific analyte for increased sensitivity of detection.
  • CMSA comprises the fixation and activation of complement by interactions between cell subset specific surface membrane proteins, and monoclonal or other antibodies. The initiation of the complement fixation process results in the production of the C3a peptide in quantities directly proportional to the extent of complement fixation.
  • One embodiment of CMSA comprises use of a soluble immunogen found in the cytoplasm or released into the cellular environment. These methods and compositions are used to diagnose the presence of pathologic or other specific soluble immunogens in the cytosol or those released into the surrounding media.
  • the diagnostic assays of the present invention are able to accurately diagnose the presence of the disease state and also determine the position of the patient in the time-course of the disease or other process.
  • the present invention comprises methods and compositions for the detection of low copy number targets of interest in diagnostic specimens in the presence of a large excess of normal material.
  • the present invention can be used for diagnostic tests and has the capability to analyze specimens at the molecular, cellular, and tissue levels.
  • NTE non-specific target elimination
  • NTE detects targets and supports high limits of specificity and sensitivity.
  • Embodiments of NTE include the Haystack Processing technologies such as TPA (Target Protection Assay), RFTA (Restriction Fragment Target Assay), EAD (Enzyme Assisted Diagnostics) and CPA (Cutter Probe Assays),and other compositions and methods as described in U.S. Patent numbers 5,962,225, and 6,100,040, and U.S. Patent Application Nos.
  • the present invention is directed to methods and compositions including NTE which comprise Selective Target Monitoring technologies (STM) with Complement Mediated Signal Amplification (CMSA) and MACMSA (Membrane Associated Complement Mediated Signal Amplification).
  • STM Selective Target Monitoring technologies
  • CMSA Complement Mediated Signal Amplification
  • MACMSA Membrane Associated Complement Mediated Signal Amplification
  • the methods and compositions of the present invention comprise detection of nucleic acid and other molecular targets, but the methods and compositions of the present invention comprise diagnostics at supramolecular levels to confirm the presence of the pathologic or other cellular target in tissues.
  • STM functions on a cellular or nuclear level to negate the presence of normal cells or nuclei in the sample by the analysis of only the cell subset of interest in a very large cell specimen and has the ability to compartmentalize and assay each cell component for the analyte of interest.
  • These low copy number analytes are detected at low copy numbers by generating a signal from the specific analyte of interest, while no signal occurs from the normal or non-specific analytes present in the compartment.
  • STM comprises target analyte sorting and separation from non-specific analyte for increased sensitivity of detection.
  • STM on a cellular level comprises CMSA.
  • CMSA comprises the fixation and activation of complement by interactions between cell subset specific surface membrane proteins, and monoclonal or other antibodies. The initiation of the complement fixation process results in the production of the C3a peptide in quantities directly proportional to the extent of complement fixation.
  • CMSA is used for detection of target cells and supports NTE in any sample, particularly biological samples including, but not limited to, all body fluids, disaggregated cells, such as those derived from tissue samples, lymph nodes and fine needle aspirates, and environmental samples.
  • An embodiment of CMSA analysis on a cellular level is taught in U.S. Patent Application 09/776,568, U.S. Provisional Nos. 60/218,460 and 60/226,825, all of which are incorporated herein in their entirety.
  • the intact cell, or cell membrane ghost, or nucleus is treated with a monoclonal antibody specific for a surface protein of interest, thereby forming an Ab/Ag complex that fixes complement.
  • complement is activated to produce C3a peptides, whose quantity is directly proportional to the number of target cells present.
  • the target analyte comprises any cell subset, an HTV infected T-cell, a dysplastic cell, and a neoplastic cell or may also be a cell membrane or cell nucleus, as well as an immunogenic carcinogen or pathologic prion protein molecule.
  • C3a peptides are produced due to the interactive presence of a lipid membrane containing a unique surface protein (immunogen), a monoclonal or polyclonal antibody, and the complement cascade components.
  • the presence and quantification of the C3a peptide produced may be achieved by any number of methods known to those skilled in the art and discussed herein or in related documents.
  • the key to CMSA is the presence of a lipid membrane that functions to amplify production of the C3a peptide by the complement cascade components.
  • the present invention contemplates the use of lipid membranes found within the sample or lipid membranes that are added to the sample.
  • the methods and compositions comprising Membrane Associated Complement Mediated Signal Amplification are used to for sensitive soluble protein analysis.
  • RBC sensitized stroma comprising antibody to the unique protein attached to a RBC lipid membrane, interacts with the target analyte molecules present in the sample. Presence of the specific target analyte causes an Ag/Ab reaction to occur at the surface of the lipid RBC membrane, which in the presence of the complement components results in the full amplification of C3a peptide production and sensitive confirmation of the presence of the immunogenic target analyte.
  • MACMSA is capable of molecular confirmation of a cellular diagnostic result as is taught in U.S. Patent Application 09/776,568, U.S. Provisional Nos. 60/218,460 and 60/226,825, all of which are incorporated herein in their entirety.
  • Soluble protein or peptide targets or other immunogenic molecules, whether pathologic or not, can be analyzed by STM on a soluble cytoplasmic molecular level that is monitored by use of MACMSA.
  • MACMSA can also sensitively detect protein/peptide targets in any body fluid or other liquid sample.
  • Another function of MACMSA is to detect and monitor non-protein chemicals in solution that are immunogenic thereby fixing and activating complement via the classical pathway, and to detect and monitor polysaccharides or other related molecules that fix and activate complement via the alternative pathway.
  • MACMSA is used for detection of soluble target molecules in any biological or environmental fluid sample including, but not limited to, all body fluids, any soluble protein fluid suspension, environmental fluids, and chemical and material processing fluids containing the soluble, immunogenic target analyte.
  • Table II presents the TSE time-course and its requirements with references.
  • Table III represents some of the interactions between plasminogen (PG n ) and plasma proteins, catalogued to delineate the PG n role in the BSE/TSE infection time- course.
  • Table TV depicts some of the in vivo interactions and functions of plasminogen, catalogued to delineate the PG n function in the BSE/TSE infection time-course.
  • Table V is the Meta Screen Bovine Multiplex Diagnostic Assay, depicting the three MACMSA complement fixation assays.
  • Table VI is the Meta Screen Bovine Multiplex Diagnostic Assay, the molecular direct automated analysis of RNA.
  • STM cellular diagnostic technologies function on a cellular or nuclear membrane level to diagnose the presence of a pathologic or other cellular target, usually a cell or nuclear subset.
  • a preferred embodiment comprises use of CMSA methods for signal amplification for the sensitive detection of the pathologic cell or nucleus.
  • CMSA is based upon the activation and fixation of complement by addition to the target cell of an antibody specific to a cell surface or nuclear membrane protein.
  • the classical complement activation pathway is activated and the extent and target presence monitored by production of the C3a peptide.
  • surface carbohydrates similarjy participate by activation of the alternate complement fixation pathway also resulting in the production of the C3a peptide.
  • One embodiment of CMSA comprises use of a soluble immunogen found in the cytoplasm or released into the cellular environment. These methods and compositions are used to diagnose the presence of pathologic or other specific soluble immunogens in the cytosol or those released into the surrounding media.
  • the diagnostic assays of the present invention are able to accurately diagnose the presence of the disease state and also determine the position of the patient in the time-course of the disease or other process.
  • Signal amplification in STM on a cellular or nuclear level is directly proportional to the extent of complement fixation and activation.
  • the cell surface membrane and nuclear membrane protein markers react with the specific monoclonal or other antibody to the immunogens resulting in fixation and activation of complement.
  • cell surface polysaccharides and other materials fix and activate complement via the alternative pathway.
  • the extent of complement fixation may be monitored as a function of the number of C3a peptides produced upon activation of fixed complement molecules, known to those skilled in the art.
  • compositions comprising MACMSA comprise embodiments that function at the molecular level by using compositions comprising attachment of an antigenic epitope or a peptide comprised of numerous epitopes to an oligonucleotide that acts as a reporter probe in nucleic acid assays.
  • One embodiment of MACMSA comprises using a single epitope to produce increased numbers of C3a molecules after binding of antibody sensitized RBC stroma to the epitope in the presence of complement followed by complement fixation and activation.
  • the extent of complement fixation and activation is influenced by many factors. These factors include avidity of the epitope and monoclonal antibody, and concentration of key intermediates in the complement cascade. For example, spiking native complement with additional C3 will increase the numbers of C3a produced by the presence of a single epitope in the assay. Other factors are determined by the method of complement fixation employed, either the classical or alternate pathway and the relative effect of C3 spiking on complement fixation by each; and the use of sensitized RBC stroma used to amplify the C3a production signal from a soluble immunogen, and methods of quantification of the resulting C3a peptide. The factors influencing C3a production in MACMSA, when optimized, can provide significant C3a peptide production per single target.
  • a preferred embodiment requires the introduction of a lipid membrane to the assay namely antibody sensitized red blood cell stroma.
  • a preferred embodiment for production of RBC sensitized stroma employs the production of an IgG antibody pair, more preferably each IgG antibody has a different specificity.
  • one IgG of the pair is an IgG antiRh monoclonal antibody used to attach the antibody pair to the RBC surface, without any need for chemical modification of the RBC.
  • the second IgG of the pair is an IgG anti-epitope monoclonal antibody used to bind the epitope present on the reporter probe and to fix and activate complement.
  • Rh determinants allow attachment of the antibody pair to the RBC membrane.
  • a benefit of using the Rh determinant is that the Rh/anti-Rh complex is known to not fix complement. Any other Ag/Ab pair could also be employed in the methods and compositions of the present invention.
  • RBCs with Ab pairs are referred to as sensitized.
  • any other site could be used that is expressed homogeneously on the RBC surface.
  • an Fab or (Fab)2 fragment specific for the alternate attachment site may be used due to the absence of the Fc region on the attachment antibody fragment used.
  • the sensitized RBCs are washed and lysed in a hypotonic buffer solution and the resulting membrane material is referred to as stroma.
  • Other embodiments call for the use of digitonin to produce a more intact RBC stroma or any method, which is known to those skilled in the art.
  • the stroma is washed to remove RBC contents and resuspendedin a suitable buffer.
  • the stroma may now be used as a reagent. Addition of stroma, the reporter probe with epitope and fresh complement and cofactors allows maximal C3a production.
  • the solution may now be assayed for C3a peptide production by use of any procedure known by those skilled in the art, such as ELISA and sensitized RBC lysis or any other method known by those skilled in the art.
  • complement fixation and activation is quantified by a novel method, namely detection of production of the inactive complement peptides (ICP), C3a.
  • ICP inactive complement peptides
  • Detection of the ICPs, preferably C3a is achieved by assays for proteins or peptides that are known to those skilled in the art, including but not limited to, competitive and sandwich immunoassays such as ELISA assays, immunoMTRF or assays included in the present invention such as complement mediated signal amplification (CMSA) and lysis of sensitized RBCs, and lysis of liposomes containing fluorescence and quencher molecules.
  • CMSA complement mediated signal amplification
  • Complement is a group of at least 25 glycoproteins with varying electrophoretic mobilities. Most circulate in the blood in an inactive precursor form and have effects in the body only after activation.
  • Two major functions of complement in vivo are to promote the inflammatory response and to alter biological membranes to cause direct cell lysis or enhanced susceptibility to phagocytosis.
  • Cell lysis occurs when antibody-mediated complement is fixed and activated by sequential interaction of the entire complement cascade. Most of these interactions result in the cleavage of an inactive protein with the release of small peptides in the complement response. In vitro, these peptides have no function, or are called inactive complement peptides (ICPs).
  • ICPs inactive complement peptides
  • ICPs inactive complement peptides
  • ICPs inactive complement peptides
  • chemotaxis enhancement of phagocytosis
  • alteration of vascular permeability alteration of vascular permeability
  • stability of cell membranes platelets and granulocytes.
  • inactive proteins aggregate resulting in an active protein.
  • the first complement component Cl attaches to the Fc portion of immunoglobulin molecules that have the appropriate binding site in the CH2 domain of the heavy chain. All mu (D) chains have this site, and most gamma ( ⁇ ) chains. Cl is composed of 3 subunits: Clq, Or, and Cls held together by calcium ions. If IgG is the type of antibody used, two adjacent protein antigenic sites must each bind an antibody molecule to form a doublet arrangement to provide the specific conformation for binding of the Cl complex. One IgM pentamer can bind the Cl complex. Clq binding to the FC region of the antigen/antibody complex undergoes a conformational change that activates Clr, which in turn activates Cls, and fixes complement.
  • each molecule of Clq bound or fixed to the target membrane will produce at least an equivalent number of C3 convertase molecules and the ICPs, C2a, C4a, C3a, and C5a. At least one C3 convertase molecule is formed per one Clq molecule initially bound. Thousands of surface membrane proteins are expressed on a single cell, thus activation of complement fixed by multiple sites on a single cell or nuclear membrane can produce thousands of C2a, C4a, C3a, and C5a ICPs.
  • Cls propagates the complement sequence by cleaving C4 into C4a and C4b and cleaving C2 to uncover a labile binding site.
  • C4b contains a binding sie and attaches to the cell membrane.
  • C4a is released into the solution in vivo to stimulate anaphylaxis by stimulating mast cell degranulation and histamine release, thereby increasing vascular permeability. This released peptide may be used in the present invention to amplify the signal from a target.
  • C2 attaches to the C4b molecule on the cell membrane.
  • the larger fragment C2b combines with C4b to produce C4b2b, called C3 convertase, which possesses enzymatic activity.
  • C3 convertase Each initial C4b2b molecule (C3 convertase) can generate attachment of hundreds of additional C4b2b (C3 convertase) active complexes to the cell membrane in proximity to the Clq binding site (the lipid structure is a requirement for this event), and in doing so, releases additional C4a and C2a ICPs which can be used for signal amplification methods in the present invention.
  • the third step is based on the function of all the bound C3 convertase molecules (C4b2b) to each cleave hundreds of C3 molecules in solution resulting in release of additional C3a peptide fragments into the solution.
  • This peptide has anaphylatoxin activity in vivo, and will be exploited as a signal amplification marker method in vitro.
  • the C3b larger fragment binds to the cell membrane complex or decays in solution.
  • C3b fragments by themselves are not active catalytically and do not promote cell lysis but do increase phagocytosis upon attachment to the cell (opsonin activity in vivo). The importance here is the additional production and release of C3a into the solution in vitro and plasma in vivo.
  • C3b molecules join the extensive numbers of C3 convertase attached to the entire cell membrane forming C4b2b3b5b or C5 convertase releasing the C5a ICP into the solution.
  • MAC membrane attack complex
  • C3a generation in CMSA and MACMSA is only one embodiment of a complement fixation assay, wherein C3a is the measure of the extent of complement fixation and activation.
  • C3a is the measure of the extent of complement fixation and activation.
  • any other peptide produced or any other complex MAC complex formation, etc., characteristically formed during complement fixation and activation can be used as a measure of complement fixation and activation. This is relevant to any produced stable product or stable complex formed by the classical pathway as well as the alternate pathway during complement fixation and activation.
  • Cleavage of C3 and subsequent activation of the remainder of the complement cascade occurs independently of complement fixing antibodies.
  • the activation is mediated by the cleavage of C3 into C3a which is released in solution and C3b.
  • C3b becomes stabilized by binding to the surface of a particulate activator of the alternate pathway called factor B, forming a stable C3b-factor B complex, itself interacting with a serum protease (factor D), cleaving factor B to produce C3bBb, that functions as a C3 convertase, again catalytically producing many additional C3a peptides.
  • factor B a particulate activator of the alternate pathway
  • the alternate complement activation pathway is activated by all viruses, bacteria, yeast or any other microbe containing polysaccharide or lipopolysaccharide elements in its exterior cell wall.
  • the present invention comprises novel and sensitive methods for signal amplification, called CMSA and MACMSA.
  • Activation of the complement cascade results in the production of millions of inactive complement peptides (ICPs).
  • Analysis of the sample for the detection and quantification of the ICPs results in the generation of 40 million ICPs per pathologic cell membrane, or nucleus (CSMA), and generation of 40,000 ICPs per soluble protein target or immunogenic epitope with the involvement of complement fixing Ag/Ab reactions in proximity to a lipid matrix (MACMSA).
  • ICP generation 1000-fold due to the ability of a single immunogenic epitope to fix 1000-fold less complement than an average cell membrane.
  • a preferred ICP is the peptide fragment C3a, because it is found in very high numbers after complement fixation. Production of other ICPs (C4a, C2a, and C5a) may also be detected although they provide less than one percent of the total signal generated by the detection of a single pathologic cell, nucleus, or nucleic acid species.
  • the novel in vitro use of the complement cascade to quantify the presence of a pathologic cell or nucleus is based upon monitoring the extent of complement fixation and activation as a function of the number of inactive complement peptides (ICPs) that are produced.
  • each target cell fixes thousand of complement molecules after addition of antibodies specific for the target cell surface protein and the subsequent reaction with the complement cascade.
  • the initial complement molecules that are fixed can themselves exert an additional 200-fold amplification effect.
  • These complement molecules also provide for another 200-fold signal amplification effect later in the course of the complement cascade.
  • SIGNAL AMPLIFICATION Methods of signal amplification using the classical complement pathway employ methods of CMSCA and MACMSA.
  • Signal amplification methods for the alternate pathway is similarly initiated by a step wherein a thioester on native C3 bhds to polysaccharide, such as a polysaccharide on the surface of an organism.
  • a thioester on native C3 bhds to polysaccharide such as a polysaccharide on the surface of an organism.
  • C3bBb activated Factor B or C3 convertase
  • the first signal amplification step occurs by the convertase cleaving numerous native C3 molecules producing numerous C3a peptides and additional C3b molecules that attach to the complex to form additional C3 convertase, that release additional C3a in the solution.
  • the C3 convertase (C3bBb) cleaves hundreds of C3 molecules generating additional C3b molecules, which attach to the complex and amplifies its activity. Cleavage of the C3 mediates release of hundreds of C3a ICP molecules to mediate amplificationin vivo of the immune response and in vitro signal amplification.
  • the second level of signal amplification employs the aggregation on the surface of a microorganism or a protein aggregate of numerous C3b units, Factor B, and Properdin (stabilizing protein) acts as a potent C5 convertase producing hundreds of C5a (ICPs), thus cleaving C5 to an active C5b and release of a C5a into the solution.
  • the remainder of the complement cascade is identical to later steps in the classical pathway.
  • the ICPs, generated by complement fixation of the classical complement pathway, or the alternate complement pathway are used for in vitro signal amplification target detection strategies.
  • C3a production by the alternate pathway must be empirically determined. Similar signal amplification quantification can be configured based on the cyclic C3 convertase enzymatic complexes formed. Though not wishing to be bound by any particular theory, it is believed that the absolute numbers of ICPs produced in the alternate pathway are on the same order of magnitude or greater than that observed by complement fixation and activation via the classical pathway.
  • the present invention comprises assays for measuring the presence and number of individual or combined ICPs and is not limited to the assays and embodiments disclosed herein.
  • the individual ICPs can be quantified by assays for proteins, including but not limited to sandwich ELISA assays, or similar assays that use a capture antibody bound to a solid support and a different labeled reporter antibody both specific for different epitopes on each ICP (C4a, C2a, C3a, C5a).
  • an embodiment of the C3a sandwich ELISA assay is configured using a biotinylated anti-C3a reporter antibody and is followed by addition of an IgG anti-biotin alkaline phosphatase polymer conjugate to facilitate signal generation per C3a molecule by introduction of the substrate, 1,2-dioxetanes.
  • Any other enzyme known to those skilled in the art may be used to quantify the number of C3a molecules.
  • the enzyme may provide a color signal, a fluorescent signal, or a chemiluminescent signal, all known to those skilled in the art.
  • a preferred embodiment of the signal generated by the C3a peptide molecules is mediated by the use of an anti-biotin alkaline phosphatase polymer, known to generate 4 logs of signal per polymer molecule.
  • the polymer is then reacted with a chemiluminescent substrate generating a stable light signal.
  • a chemiluminescent substrate generating a stable light signal.
  • One such substrate is the 1,2-Dioxetanes, which have been shown to detect 0.01 attomole quantities of alkaline phosphatase enzyme, translating to a ten-fold increased level of target detection by the enzyme polymer.
  • This detection system will support unprecedented high levels of target detection and, due to the nature of antibody conjugates to enzymes, will provide a relatively low background in the negative controls
  • Step I Prepare a magnetic bead with a covalently bound IgG anti-C3a capture antibody.
  • the binding can be achieved by any chemistry known to those skilled in the art such as covalently linking a carboxylated magnetic bead to the primary amine on the n- terminal end of the antibody molecule, or any other chemistry known to those skilled in the art.
  • Step II The magnetic bead is washed to remove non-bound capture probes and Step III. Conjugated beads are added to a sample containing the C3a peptide in solution, which is mixed and incubated. Step IV. The magnetic beads are washed to remove non-specific bound materials Step V. Addition of another antibody, IgG anti-C3a, which has reporter function and is specific for a different epitope on the C3a peptide molecule. This antibody possesses an alkaline phosphatase (AP) polymer covalently attached to it. This may be generated by any method known to those skilled in the art, the preferred one being attachment antibody N-terminal amine of the maleimide derivative of the AP polymer, which results in covalent bond formation.
  • AP alkaline phosphatase
  • Step VI Wash to remove unbound reporter probe. The number of washes and the wash buffer may be critical in resolving non-specific signal from unbound reporter enzyme.
  • Step VII Addition of the magnetic beads to a solution containing the 1,2-Dioxetane substrate and incubate under conditions for the production of a stable chemiluminescent signal.
  • the reporter antibody and hence the target, is detected by the activation of a chemiluminescent substrate to produce light by enzymatic catalysis.
  • the reporter antibody can also be detected using immuno MTRF methods as disclosed in U.S. Patent Application No. 09/443,633 or by conjugating a label, such as a single molecule of fluoroscein isothiocyanate, to each ICP reporter antibody.
  • Another method of the present invention for C3a quantification comprises steps to identify and quantify the specific ICP of interest using sensitized RBCs conjugated with anti-specific ICP antibodies, which will only react with the free-floating ICPs in solution.
  • RBCs linked to anti-ICP monoclonal antibodies will in the presence of complement undergo complement-mediated immunoerythrocyte lysis, releasing hemoglobin for quantitation.
  • the extent of RBC lysis is directly proportional to the quantity of ICPs produced and targets present.
  • Another method for assay of C3a production would be the use of IgG anti-C3a antibody imbedded on the surface of a liposome containing fluorescence and quencher molecules in close proximity, so that no fluorescent signal can be detected.
  • Introduction of a C3a peptide to the antibody-sensitized liposome, in the presence of the complement components will result in complement mediated lysis of the liposome, releasing the fluorescence and quencher molecules into the solution. Their release and separation can be monitored by the detection of a fluorescent signal.
  • the extent of liposome lysis is directly proportional to the quantity of ICPs produced and targets present.
  • One embodiment of the present invention comprises methods to identify and quantify specific ICPs of interest comprising use of sensitized RBCs that are conjugated with specific anti-ICP antibodies that will only react with the free-floating ICPs in solution and in the presence of fresh complement, result in red blood cell lysis upon binding of free
  • the sensitized or immuno RBCs can be generated by stripping the RBCs with a proteolytic enzyme such as bromelain, ficin, or papain and by other methods known to those skilled in the art, that attach the ICP specific antibodies to the RBC surface, producing sensitized immunoerythrocytes which bind the free floating ICP in solution.
  • a proteolytic enzyme such as bromelain, ficin, or papain
  • This attachment of an antibody to the stripped RBC surface by simple exposure of the antibody to the erythrocyte provides a non-covalent attachment of the antibody molecule, and is sufficient for some applications. Due to the fact that chemical modification of the RBC surface involves increased fragility of the modified RBC, which may result in the spontaneous release of hemoglobin and make quantification of the ICP peptides difficult, other methods are also contemplated by the present invention.
  • a novel process for production of antibody sensitized RBCs is mediated by the use of an IgG antibody pair.
  • the characterization of the molecule is as follows:
  • IgG molecules are attached to each other by any method known to those skilled in the art, where the attachment does not interfere with the antibody binding sites.
  • One antibody must be specific to any of the ICP peptides for assay; for example, the IgG anti-C3a antibody used in the C3a peptide assay. Other embodiments require this antibody to be specific for any immunogenic epitope on the target. 3.
  • the other antibody is specific for an antigen on the RBC.
  • a most preferred embodiment comprises use of an antibody specific for the Rh determinant. The Rh determinant extensively covers the RBC membrane with thousands of molecules and this is the site at which the antibody pair binds to the erythrocyte. This antigen antibody reaction does not fix complement.
  • the Rh determinants on the RBC surface are responsible for bringing the antibody to the C3a and other peptides in close proximity to the lipid membrane surface without altering the stability of the immunoerythrocyte.
  • Another embodiment for use of the antibody-pair molecule may involve its use in vivo to neutralize the activity of a pathologic analyte.
  • This analyte may be a viral particle, antibody molecule, dysplastic or cancer cell, and even an immunogenic environmental carcinogen. Attachment of the IgG anti Rh-IgG anti pathologic analyte antibody pair to the RBC surface would facilitate the immediate attachment and neutralization of the pathologic analyte to any of the RBCs that have been sensitized.
  • MACMSA requires the interaction of a lipid/antibody complex with a soluble protein or reporter probe immunogenic epitope.
  • the preferred embodiment for production of this complex is the sensitization of the RBCs by the aforementioned method with subsequent lysis of the sensitized RBCs in a hypotonic buffer solution resulting in the production of antibody attached lipid membrane (RBC stroma) that will exert the full signal amplification effect of the immunogenic epitope or soluble protein by the MACMSA process.
  • Stroma production is achieved by placement of the immunoerythrocytes in a hypotonic buffer resulting in RBC lysis and membrane ghost formation. The stroma is then washed in buffer and resuspended in buffer for use as a reagent. Any other method known to those skilled in the art may be used.
  • One embodiment of prion sorting in a protein sample can be achieved by attachment of a monoclonal antibody at its C-terminal end to a magnetic bead.
  • the magnetic beads are placed in a large volume solution such as plasma or brain biopsy extract or any other and mixed.
  • the epitopes available for interaction on the C-terminal end of the prion molecule remain exposed in both the normal and aberrant prion molecule.
  • the magnetic beads are collected with a magnet and washed in buffer. All the prion present in the sample will be separated from all other soluble proteins.
  • the C- terminal antibody will capture the normal and pathologic prions due to the continued accessibility of the epitopes of both forms even after the transition has occurred.
  • the prion sorted magnetic bead is treated with a monoclonal antibody available to the N-terminal end of the prion molecule (the ⁇ sheet isoform end) that is labeled with an alkaline phosphatase polymer or any label known to those skilled in the art. Both are incubated and washed in buffer.
  • the N-terminal end of the pathologic prion has undergone a transition from ana to a ⁇ sheet form. During this transition, epitopes, normally found on the N-terminal end are covered and new epitopes exposed. To date no monoclonal antibodies have been found that successfully discriminate the ⁇ sheet form (normal prion) from the ⁇ sheet form of the aberrant prion.
  • Monoclonal antibodies specific for the N-terminal end of the pathologic prion are necessary for use in these sensitive diagnostic assay embodiments.
  • the magnetic beads are exposed to a chemiluminescent substrate, such as the
  • 1,2-Dioxetanes which would be able to detect 0.01 attomoles quantities of alkaline phosphatase enzyme. Theoretically, supporting increased sensitivity than that achieved by prion precipitation by sodium phosphotungstate and time resolved fluorescence previously mentioned.
  • scrapies infection can be blocked by inhibition of B cell formation, T cell formation, and complement depletion (Clq deficient host).
  • the disease inhibition can be reversed by reestablishment of T and B cell production and complement activity (reversal of Clq deficiency).
  • Table II presents a number of conclusions drawn relative to the TSE time-course and its requirements (appropriate references are indicated).
  • the T cells may function in antigen (aberrant prion) display, in order for B cell production of a weak initial antibody response (IgM initially).
  • IgM initially a weak initial antibody response
  • Complexation of the anti- prion antibody and the aberrant prion will fix and activate plasma complement thereby depositing C3b and other complement fragments on the aberrant prion antibody complex.
  • the C3b may then interact with the M cell (in intestinal Peyer's patches of man) surface C3b or other complement receptor, resulting in ingestion via phagocytosis of the Ag/Ab C3b complex.
  • BIOLOGICALLY RELEVANT PLASMINOGEN PROTEIN INTERACTION INVOLVES ANCHORING OF THE ZYMOGEN THROUGH LYSINE BINDING SITES IN THE KRINGLE DOMAINS.
  • Table IV depicts some of the known documented in vivo interactions and functions of plasminogen, catalogued to delineate the PG n function in theBSE/TSE infection time-course.
  • Plasminogen functions presented herein pose a strong case for the requirement of plasminogen on the PrP sc molecule for the invasiveness of the prion in early stage disease. This includes normal prion accumulation and invasion of the aberrant prion into tissues necessary at some stage of the infectious PrP sc time-course.
  • PrP entry at the site of the M Cell in the intestinal Peyers patches m man is supported by 1) an understanding of mucosal immunology (Mucosal Immunology, 1999), ⁇ p which is the effector site for vaccines in the body, 2) acceptance of the PrP infection requirement for active B cells and T cells, and 3) the presence of the C3b complement receptor on the M Cell macrophage (fixed monocyte) surface.
  • the PrP sc complex Upon formation of the PrP sc /PG n /antibody/C3b the PrP sc complex enters the lymphatic system by some method, where it travels to all lymphoid organs including the tonsils and ultimately the brain. Movement of the PrP sc complex in the lymphatic system may afford the complex protection from phagocytosis by the C3b receptors present on numerous phagocytic cell surface in phagocytic departments that are not involved in the infection and may even limit the infection by disintegrating the PrP sc complex.
  • C3b receptors are found on all polymorphonuclear granulocytic macrophages in the circulation and all fixed monocytic macrophages in the body, some protective effect would be required.
  • PrP 50 infection An alternate sequence of events for PrP 50 infection could entail PrP sc entry to the blood, post ingestion, followed by complex formation (host IgM antibody/primary antibody response, complement, and plasminogen addition), and transport to the brain, whereupon glial fixed monocytic cells possessing C3b receptors could phagocytize and internalize the PrP sc complex and further the disease course.
  • Peripheral infection in particular, oral uptake of TSE infected material is epidemiologically most relevant for BSE, Sheep Scrapie, Kuru, and nv CJD.
  • PrP Presence of PrP , only possible for use as a target if a monoclonal antibody is produced that will discriminate PrP sc from PrPc or PrP (not as yet known to be in existence).
  • early diagnostic assays for a disease be highly specific, highly sensitive and capable of automation, as well as cost efficient, to assess the state of the animal or human, as well as for monitoring residual disease, once a treatment or cure is available.
  • the high specificity of the assay defined as the lack of false positive results, can be provided by a multi-step procedure that is designed to limit the generation of signal by non-infectious target analyte (prions).
  • the high sensitivity of the assay defined as the lack of false negative results, can be provided by the ability to screen large amounts of sample analyte, namely prion from a large volume of plasma, for the aberrant prion.
  • Ease of use of the assay allows for widespread use in limiting epidemics by monitoring the spread of disease and maintaining surveillance of the state of the animal or human. Furthermore, combined manual and automated assays are readily achieved with the ability to screen volumes of plasma sample.
  • NTE non-specific target elimination
  • the Haystack Processing invention Selective Target Monitoring (STM, previously presented), mediated by Complement Mediated Signal Amplification (CMSA) and the Membrane Assisted Complement Mediated Signal Amplification (MACMSA), also achieve such by the use of a signal generation process initiated by an immunogenic protein or other immunogenic target and permits no signal to be generated by a non-specific target analyte.
  • All Haystack Processing strategies result in direct analysis of previously non-analyzable large samples of analyte with the ability to detect the presence of very low copy number DNA, RNA, cell subsets, and protein a d other immunogenic targets of interest.
  • the MACMSA process provides a complement fixation assay for immunogenic targets.
  • the MACMSA assay has been presented earlier and is based upon C3a generation as a result of complement fixation and activation, wherein the increasing number of targets produces increasing levels of C3a.
  • TSE META SCREEN ASSAY TARGETS FOR PrP 50 DETECTION IN BLOOD AND OTHER HOST FLUIDS EARLY IN The INFECTIOUS TIME-COURSE
  • Meta Screen Assay functions by detection of plasminogen, host primary antibody (IgM) and a complement fixation product C3b, C3d, C4b, or other complement cascade product or fragment on a PrP sc molecule, not found on the PrP c or PrP prion molecule.
  • This novel method for sensitization of RBCs uses the D antigen expressed homogeneously on the entire RBC surface to attach the molecule pair.
  • the D antigen was selected due to its inability to fix complement upon complexation with the anti-D antibody of the molecule pair.
  • other sites on the RBC may also be used, however, since complement fixations must not occur, an Fc deficient Fab or (Fab) 2 fragment to another homogeneously surface expressed RBC protein or other similarly functioning moiety may be used in place of IgG anti-D.
  • the method for sensitization of the intact RBCs by the molecule pair has been presented in related applications.
  • Sensitized RBC stromal may be produced from sensitized RBCs by any method known to those skilled in the art. One preferred example may involve the use of digitonin to produce high quality stroma.
  • Step I Isolation of all the prion in a sample (PrP and PrP sc ) by attacliment to a magnetic bead coated with a charged moiety known to those skilled in the art, that will specifically bind this prion protein subset.
  • Step II Addition of the monoclonal antibody specific to PrP sc in the form of
  • sensitized RBC stroma (IgG anti PrP sc -IgG anti-D is the sensitization molecule pair).
  • Step III Addition of the immune complement reagent and incubation under conditions to generate the amplified signal, namely, the C3a peptide.
  • Step IV Assay for the C3a peptide by any method known to those skilled in the art.
  • STRATEGY II This process eliminates the need for a discriminatory monoclonal antibody for PrP and PrP sc . It has been reported that the PrP sc molecule binds plasminogen, the inactive zymogen proteolytic enzyme, while the PrP does not bind the zymogen. Furthermore, documented observations, previously discussed herein, also support the attacliment of an IgM antibody to the aberrant prion. This IgM antibody would be produced as a low titer (possibly currently undetectable by current ELISA assay) primary, antibody response to a protein antigen, similar to a protein vaccine. Also, the model presented herein calls for complement fixation or C3b or other complement fragments to be attached to the prion/3 target complex presented. The steps of this process are:
  • Step I Isolation of all the prion in a sample (PrP and PrP sc ) by attachment to a magnetic bead coated with a charged moiety known to those skilled in the art, that will specifically bind this prion protein subset.
  • Step II Addition of the monoclonal antibody specific for any non-Kringle region site on the PG n molecule.
  • plasminogen is known by those skilled in the art to participate in fibrinolysis, metastasis of cancer cells into tissue, and release of normal prion proteins from blood platelets, thereby insuring that the PrP ⁇ 0 molecule possesses invasive potential as well as securing the flow of blood platelets and providing the continuous supply of PrP substrate for conversion to PrP sc and the resultant production of the amyloid fibrils and plaques in brain tissue continuous in the disease time-course.
  • plasminogen is prevalent in blood at high concentration and PrP upon introduction to the body, due to reaction kinetics, based on concentrations of the reactants, should be spontaneously bound to the PrP sc molecules present.
  • antibody (monoclonal) specific to the host IgM and another antibody (monoclonal) specific to C3b may also be added. All three antibodies should indirectly detect the early time-course PrP sc /PG n /host IgM/C3b complex.
  • Step III Addition of the immune complement reagent with cofactors and incubation under conditions to generate the amplified signal, namely, C3a peptide production.
  • Step IV Assay for the C3 a peptide by any method known to those skilled in the art.
  • STRATEGY III This process eliminates the need for use of the immune complement reagent, while still focusing on detection of the plasminogen moiety attached to the PrP sc molecule, absent from the PrP molecule.
  • the activation peptide of the plasminogen post PrP sc binding must be sterically available for removal by any activation molecule known to those skilled in the art.
  • Step I Isolation of all the prion in a sample (PrP and by attachment to a magnetic bead coated with a charged moiety known to those skilled in the art, that will specifically bind this prion protein subset.
  • Step II Addition of an activation molecule under conditions that will convert the plasminogen zymogen proenzyme to the active enzyme plasmin, known by those skilled in the art.
  • Step III Addition of another zymogen or proenzyme that the plasmin will activate, or addition of a substrate that the plasmin will catalytically modify, both steps initiate generation of a signal.
  • Any zymogen, cascade, or any enzymatic reactionknown to those skilled in the art may be used. The preceding is referred to as Zymogen Mediated Signal Amplification or ZMSA and was presented previously (provisional patent number 60/226,823).
  • Step IV Addition of a substrate to the second zymogen (proenzyme) to catalytically generate a detectable signal.
  • Step V Detection of the amplified signals, generated in Steps III and IV, by any method known to those skilled in the art.
  • STRATEGY IV This process comprises use of steps involving serine proteases activating immune complement.
  • the PrP sc plasminogen complex is treated by any method known to those skilled in the art resulting in the formation of the active enzyme, plasmin.
  • the resulting plasmin should activate the complement pathway by cleavage of C3 into C3a pathway resulting in the increasing generation of the C3a signal peptide.
  • Step I Isolation of all the prion in a sample (PrP and PrP sc ) by attachment to a magnetic bead coated with a charged moiety known to those skilled in the art, that will specifically bind this plasma protein subset.
  • Step II Addition of any activation molecule, known by those skilled in the art, under conditions that will convert the plasminogen zymogen proenzyme to the active enzyme plasmin.
  • Step III Addition of immune complement reagent and cofactors under conditions that will allow the activation of complement, resulting in the generation of the amplified signal, the C3a peptide.
  • Step IV Assay for the C3a peptide by any method known to those skilled in the art.
  • STRATEGY V Monoclonal antibodies currently available that bind, PrP sc , PrP c and
  • PrP can be attached to magnetic bead and used to remove all prion proteins from the sample. This will support large sample testing and will allow thorough removal by washing of non-specific moieties associated with title prion fraction, such as plasma plasminogen, plasma IgM, and plasma C3b.
  • the sensitive C3a complement fixation MACMSA assay can not only detect low copy number aberrant prions, but may also include detection of other diseases of the host.
  • One embodiment in cattle may provide early and sensitive multiplex detection for the following:
  • VSV Vesicular Stomatitis Virus
  • C3a complement fixation system is the production of the molecule pair sensitized RBC stroma. The following correlates the disease with the specific molecule pair sensitizing antibody:
  • these diseases include any number of and all known, and the targets selected may be any known, as long as one possesses an accompanying antibody, antibody fragment, or other molecule with similar function.
  • This antibody specific for the target becomes one part of an antibody pair, a molecule pair; the other antibody of the pair is any antibody and related moieties previously discussed that fimctions to attach the molecular pair to any surface on the red blood cell or stroma to be sensitized.
  • this attachment site is the Rh POS (R2R2) surface protein on the RBC.
  • the first step involves isolation of all prion in the plasma sample by attachment of both PrP sc and PrP c (PrP) to antibody coated magnetic beads.
  • the antibody removes all prion from the plasma and allows washing of the prion material (the Mab is specific to the C terminal end of all prion). Washing removes non- specifically bound plasminogen bovine IgM, and exogenous C3a, C3b, C3d and C4b from the plasma attached to the prion coated magnetic beads. It must be remembered that plasminogen, endogenous host antibody (IgM) and C3a, C3b, C3d and C4b is found in normal plasma, necessitating washing all bound prions to remove these non-specific moieties.
  • IgM endogenous host antibody
  • C3a, C3b, C3d and C4b is found in normal plasma, necessitating washing all bound prions to remove these non-specific moieties.
  • B Plasma Aliquot Secured For
  • the prions after thorough washings, bound to the magnetic beads, are treated with the three RBC sensitized stromas previously mentioned. An aliquot of the remaining plasma is directly added to the four RBC sensitized stromas that relate to the specific virus and bacteria presence that were previously mentioned.
  • These microorganisms may fix complement by either the classical pathway or the alternate pathway. Plasma containing intact microorganisms, upon introduction to the corresponding sensitized stroma (anti-microbe antibody is present), will result in complement fixation by the classical pathway; however, carbohydrate present on the microorganism may similarly fix complement via activation of the alternate pathway (note: activation of the alternate pathway also leads to C3a production).
  • the total prion content on the magnetic bead is released by any method known to those skilled in the art (ex. Chemical, acidity, alkalinity, treatment followed by bead removal and solution neutralization, etc.) into a solution containing the three sensitized stroma (specific to plasminogen, host IgM, C3b, C3d, and C3b to screen selectively for PrP in a complement fixation MACMSA assay where PrP and PrP are transparent to the assay.
  • the Meta Screen Bovine diagnostic assay is presented in Table V and Table VI.
  • the diagnostic process is a multiphase approach in a multiplex diagnostic assay.
  • the Meta Screen Assay presented will involve bovine diagnostic multiplex assay to early detect a number of targets responsible for a number of disease states early in the bovine infection time-course.
  • Similar Meta Screen Assays may be configured for a human multiplex diagnostic (including a target responsible for Creutzfeld Jacob Disease (TSE in humans), such as that responsible for the anti-prion antibody to nv CJD, as well as other targets such as pre-cancerous (dysplasia), cancer, metastatic cancer, residual disease and any other applicable and similar target.
  • TSE Creutzfeld Jacob Disease
  • the Meta Screen Assay may also be converted into an environmental panel wherein, immunogenic chemical pollutants may be multiplex assayed along with other targets such as microbial contaminants, carcinogenic molecules, and any other conceivable and applicable target that meets the immunogenic criterion of the process, the immunogenic property of the target.
  • targets such as microbial contaminants, carcinogenic molecules, and any other conceivable and applicable target that meets the immunogenic criterion of the process, the immunogenic property of the target.
  • Meta Screen diagnostic panels may be configured for all biological organisms and their diseases that can be determined to have an immunogenic target and a monoclonal antibody specific for that target.
  • MACMSA As a complement fixation assay based on a number of targets, MACMSA would reflect the extent of complement fixation known to those skilled in the art and as such allow quantification of the extent of signal amplification.
  • amplified products of complement fixation and activation could include all peptides produced by fixation and activation of the cascade as well as the formation of any of the cascade structures, or any other moiety produced by this fixation and activation.
  • the molecule pair in one embodiment is a monoclonal IgG antibody specific to the target, coupled by known chemistries to another IgG antibody specific to the Rh D protein on the RBC, the site for attachment of the molecule pair and other possible attachment sites.
  • the attachment moiety may also be an antibody fragment, or other attachment molecule specific for any homogeneously expressed protein on the surface of the RBC.
  • the D site of molecule pair attacliment was selected due to the known inability of the D/IgG anti-D to fix complement. Thus molecule pair attachment will sensitize the
  • RBC without chemical modification and without complement fixation or activation, along with the antibody fragments Fab or (Fab) 2 ⁇ and similar functioning molecules can be used, providing complement is not fixed or activated.
  • the goal of the assay is to determine the presence of the predicted prion/protein complex that would be found early in the infection.
  • This complex as stated is PrP sc /plasminogen/host IgM antibody/C3b, C3d, and/or C4b.
  • Step I The Sample (Aliquot I) Plasma from a single animal or pools of plasma from several animals may be used as a sample. An aliquot of 100 ⁇ l can be assayed on a lobotic analyzer device The ability to analyze a large volume sample is known by those skilled in diagnostics to assure the detection of the pathologic target in the earliest stages of the host infection time-course. If necessary for early BSE detection, a 50cc or larger plasma sample can be manually prepared and the concentrated prions introduced into the robotic platform for automated PrP complex target detection. To achieve this, magnetic beads would be added to the large volume plasma sample.
  • Step II Magnetic Bead Addition Magnetic beads are added that are coated with an IgG monoclonal antibody that or any other molecule known to bind PrP sc , PrP c , and PrP, namely all prion forms, known by those skilled in the art.
  • Step III Wash
  • any method known by those skilled in the art may be used to dissociate the prions from the magnetic beads, place them in a separate tube and remove the stripped magnetic beads.
  • Rh Pos molecule pair sensitized Rh Pos (R2R2) sensitized stroma.
  • the R2R2 Rh Pos type was selected for its greatest RBC surface expression and strongest interaction with the anti-D moiety of the molecule pair. Any other Rh Pos type may , also be used.
  • the molecule pairs are:
  • the attachment site of the molecule pair should be homogeneously expressed on the RBC surface. The above are the preferred embodiment but all other similarly functioning attachment molecules have been discussed.
  • Step VI Incubate To Allow The Antigen/Antibody Reaction To Occur
  • Step VII Complement and Cofactor Addition Complement, calcium and magnesium are added to the prion-stroma mixture.
  • One embodiment calls for use of human complement due to the fact that the C3a peptide ELISA used to quantify C3a is composed of monoclonal antibodies (capture and reporter) specific to the human C3a peptide. Calcium and magnesium are each added at a concentration of 20 mM.
  • Step Vffl Incubate at Room Temperature
  • Step LX Assay for C3a Peptide
  • the prion stroma/complement mix is mixed by periodic aspiration up and down in the pipette tip and, upon completion of the incubation, the stroma is allowed to settle to the well bottom; an aliquot of supernate is removed of 50 to 100 ⁇ l to quantify C3a peptides present.
  • Quidel Corporation possesses a C3a (human) sandwich ELISA using horseradish peroxidase to generate a color substrate signal.
  • C3a quantification assay embodiment currently under development is a C3a sandwich ELISA using magnetic beads coated with the capture antibody IgG anti C3a and the reporter antibody another IgG anti C3a labeled with biotin (for example), and subsequent use of a streptavidin alkaline phosphatase conjugate, which, coupled with a sensitive chemiluminescent substrate (1,2 Dioxetane) known to those skilled in the art, provides a more sensitive assay for C3a quantification.
  • a sensitive chemiluminescent substrate (1,2 Dioxetane
  • the goal herein, is to detect the presence of microbes, bacteria, fungi, virus, etc. in the sample.
  • the complement fixation reaction involves the presence of immunogenic proteins found on the microbe surface and requires the possession of the IgG anti-microbe surface protein molecule attached to the IgG anti-D (the molecule pair) used to sensitize the stroma.
  • Plasma from a single animal or pools of plasma from several animals may be used as a sample.
  • an aliquot of 100 ⁇ l can be assayed on a robotic analyzer devise.
  • the ability to analyze a large volume sample is known by those skilled in diagnostics to assure the detection of the pathologic target in the earliest stages of the infection time-course.
  • a 50cc or larger plasma sample can be manually prepared and the microbes present can be concentrated by any method known to those skilled in the art.
  • the concentrated microbes are nextprocessed by direct addition to the various sensitized stromas. Step II: Sensitized Stroma Panel Addition
  • the sensitized stroma panel in this embodiment, will detect the presence of Vesicular Stomatitis Virus (VSV), Foot and Mouth disease virus (FMD), Mycobacterial species, Brucella species and even the Nemavirus that some believe to be the etiologic agent for BSE (Narang, 1998).
  • VSV Vesicular Stomatitis Virus
  • FMD Foot and Mouth disease virus
  • Mycobacterial species Brucella species
  • Brucella species etiologic agent for BSE (Narang, 1998).
  • the molecule pairs used to sensitize the Rh Pos (R2R2) RBC stroma are:
  • Step III Incubate To Allow The Microbe/ Antibody Reaction To Occur
  • One embodiment calls for use of human complement due to the fact that the C3a peptide
  • ELISA used to quantify C3a is composed of monoclonal antibodies (capture and reporter) specific to the human C3a peptide. Calcium and magnesium are each added at a concentration of 20 mM.
  • Step V Incubate at Room Temperature Incubate the mixture at 24°C for 30 to 60 minutes to allow complement fixation by the target/stroma complex and activation resulting in increased or amplified levels of C3a production.
  • Step VI Assay for C3a Peptide
  • microbe/stroma mix is mixed by periodic aspiration and, upon completion of the incubation, the stroma is allowed to settle to the well bottom; an aliquot of supernate is removed of 50 to 100 ⁇ l to quantify C3a peptides present.
  • Quidel Corporation possesses a C3a peptide sandwich ELISA using horseradish peroxidase to generate a color substrate signal.
  • C3a quantification assay embodiment currently under development is a C3a sandwich ELISA using magnetic beads coated with the capture antibody IgG anti C3a and the reporter antibody another IgG anti C3a labeled with biotin (for example), and subsequent use of a streptavidin alkaline phosphatase conjugate, which, coupled with a sensitive chemiluminescent substrate (1,2 Dioxetane) known to those skilled in the art, provides a more sensitive assay for C3a quantification.
  • a streptavidin alkaline phosphatase conjugate which, coupled with a sensitive chemiluminescent substrate (1,2 Dioxetane) known to those skilled in the art, provides a more sensitive assay for C3a quantification.
  • the goal, herein, is to confirm detection of the presence of a microbe in the sterile plasma of the cow.
  • This approach is based on the complement activation produced by the Alternate Complement Pathway in the absence of the antibody on the sensitized stroma. It is known by those skilled in the art that intact microbes possess carbohydrate surface moieties, which when exposed to complement, with its cofactors activates complement and produces C3a peptides proportionate to the number of microbes present in the sample.
  • This internal confirmation can detect low copy microbial targets in any fluid, such as plasma, urine, cerebrospinal, and amniotic.
  • Plasma from a single animal or pools of plasma from several animals may be used as a sample.
  • An aliquot of 100 ⁇ l can be assayed on a robotic analyzer devise.
  • the ability to analyze a large volume sample is known by those skilled in diagnostics to assure the detection of the pathologic target in the earliest stages of the infection time-course.
  • a 50cc or larger plasma sample can be manually prepared and the microbes present can be concentrated by centrifugation, dialysis, or any other method known to those skilled in the art.
  • the concentrated microbes are next processed by direct addition of complement.
  • the goal of this phase of the assay is to confirm the presence of the target microbe by another signal amplification method, comprising direct activation of the Alternate Complement Pathway by the direct presence of the microbe, in the sterile sample, resulting in increased C3a peptide production
  • Complement containing properdin and Factor B as cofactors, is directly added to the plasma sample for analysis. Interaction of the microbe and complement will activate complement and result in C3a peptide production.
  • One embodiment of the assay calls for the use of human complement, due to the fact that the C3a peptide ELISA, used to quantify C3a is composed of monoclonal antibodies (capture and reporter) specific to the human C3a peptide. Step III: Incubate at Room Temperature
  • microbe/stroma composite is mixed by periodic aspiration up and down in the pipette tip and, upon completion of the incubation, the stroma is allowed to settle to the well bottom; an aliquot of supernate is removed of 50 to 100 ⁇ l to quantify C3a peptides present.
  • Quidel Corporation possesses a C3a peptide sandwich ELISA using horseradish peroxidase to generate a color substrate signal.
  • C3a quantification assay embodiment currently under development is a C3a sandwich ELISA using magnetic beads coated with the capture antibody IgG anti C3a and the reporter antibody another IgG anti C3a labeled with biotin (for example), and subsequent use of a streptavidin alkaline phosphatase conjugate, which, coupled with a sensitive chemiluminescent substrate (1,2 Dioxetane) known to those skilled in the art, provides a more sensitive assay forC3a quantification.
  • a streptavidin alkaline phosphatase conjugate which, coupled with a sensitive chemiluminescent substrate (1,2 Dioxetane) known to those skilled in the art, provides a more sensitive assay forC3a quantification.
  • an automated analysis technique has bee presented for automated RNA isolation and direct RNA analysis using RP-TFO RNA TPA diagnostic analysis process.
  • RP-TFO diagnostic process works well with single stranded mRNA or other single stranded RNA targets, such as found in VSV and FMD infections.
  • mRNA can be detected for any derepressed gene in the DNA of the microbe, for example, the mRNA, which would establish antibiotic resistance to the microbe.
  • BSE infection event (described and referenced herein)
  • PrP sc infection event one scheme for BSE and PrP sc infection would involve antigen (PrP sc ) DISPLAY by the appropriate T lymphocyte and subsequent presentation to a B cell subset that would produce an antibody specific to PrP sc .
  • This antibody would be required to fix complement, a requirement also found in an early infection event in scrapies (described and referenced herein). It could be an IgM or other antibody that is characterized as a single molecule that alone can fix complement.
  • the complement requirement would place complement fragments C3b, C3d, C4b and other molecules on the PrP sc /plasminogen/host antibody complex.
  • phagocytic cells possess one of a number of complement fragment receptors, primarily functioning in opsonized clearance of antigen/antibody complexes and microbial organisms, which are both opsonized in vivo.
  • the following chart presents phagocytic cell types, all possessing the C3b receptor for internalization of the antigen, which in this discussion is the PrP ⁇ /plasminogen/host antibody/complement fragment complex:
  • the singular point of disruption of the proposed time-course is the phagocytic event itself, no matter where it occurs. It is known that some viruses, such as HIV, form low grade infections in monocytes (fixed tissue and immature circulating types), survive and advance the disease state. It is also understood that a similar virus phagocytized and internalized by a different phagocytic cell subset namely the circulating polymorphonuclear granulocytes would be destroyed. This is a function of different digestive vesicles and enzymes being present in different phagocytic compartments.
  • a therapeutic embodiment of the molecule pair has been presented in related applications where it has been proposed that immunogens in the circulation can be removed from the circulation mediated by a method for attachment of the immunogen in vivo to the molecule pair sensitized RBCs and that the nature of this attachmentexclusively predisposes the phagocytosis by the polymorphonuclear granulocytes in circulation as opposed to the fixed tissue monocytes regulated primarily by the dispersal of the sensitizing antibody on the RBC surface, represented by the following chart:
  • the molecule pair is characterized as being a pair of monoclonal antibody molecules covalently attached, one being specific for the target, namely the PrP 80 complex and the other specific for a site that is homogeneously expressed on the bovine RBC surface.
  • the life expectancy of a bovine RBC is approximately four months and a number of proteins are homogeneously expressed on the surface.
  • the molecule pair attachment site would be any one that is homogeneously expressed over the entire surface.
  • the attachment antibody cannot fix complement, and as such, an antibody fragment (Fab) or (Fab) 2 devoid of the Fc region would be used to avoid complement fixation and sensitized RBC clearance by the circulatory system.
  • the antibody recognizing the PrP complex would be the IgG anti complement fragment antibody, identical in function to the complement receptors on the phagocytic cell surface.
  • the molecule pairs ofthe preferred embodiment of the invention would be: IgG anti C3b - (Fab) 2 anti bovine RBC antigen, anti C3d - (Fab) 2 anti bovine RBC antigen, anti C4b - (Fab) 2 anti bovine RBC antigen, and similar for any other complement fragment attached to the PrP sc complex.
  • the stated molecule pair is used to in vivo sensitize the bovine RBCs (4 month life expectancy).
  • the IgG anti complement fragment antibody attached to the RBC surface will compete with the monocytic phagocytic cells for the PrP ⁇ /plasminogen/host antibody/complement fragment complex and understanding that the sensitized RBCs would greatly outnumber the fixed tissue monocytes, one can prevent the PrP 0 complex intemalization by the "normal" route and attach the complex to sensitized RBCs via the molecule pair. This will interrupt the nomial BSE infection course.
  • polymorphonuclear granulocytic phagocytes also express Fc receptors on their surface, which aid in infernalization of any complex containing the Fc region. This should further assist in interruption of the normal infection course of the PrP sc complex. In reality, this may not play an important role in phagocytic compartment redirection probably do to the presence of Fc receptors in the fixed monocytes of the spleen and liver, which are responsible for destruction of antibody coated RBCs (Fc regions present).
  • the RBCs with attached PrP sc complex are phagocytized as the complexes bind to the molecule pair sensitized RBCs.
  • the zipper mechanism known for PMN phagocytosis attaches the PMN to the first PrP sc complex which remains intact in the circulation to mop up or attache additional PrP sc complexes, causing more complete phagocytosis until a certain threshod of PrP sc complexes is met, which supports the total engulfment and destruction of the sensitized RBC and all the PrP sc complexes that are attached.
  • the PrP sc complex is effectively neutralized upon binding to the sensitized RBC and no downside exists for its delayed destruction, and two, binding of the PrP sc complex to the molecule pair sensitized RBC will not fix additional complement and release toxic hemoglobin into the circulatory system, due to the presence of decoy acceleration factors (DAF) found on blood elements and body tissues that prevent formation of the membrane attack complex (MAC), a group of late complement cascade proteins that form a hole in the cell membrane. DAF on the RBC membrane inhibitsMAC formation.
  • DAF decoy acceleration factors
  • the mechanism of action of DAF involves the acceleration of destruction of classical and alternate pathway C3 and C5 convertases (Nicholson-Weller, 1982; Medof, 1984; Pangburn, 1986; Fujita, 1987).
  • This new phagocytic compartment would prevent the PrP sc complex from pursuing its "normal" course and the PrP 80 complex intemalization in the granulocytic, phagocytic compartment would destroy the complex and limit resolve the infection, as well as any other different compartment involved in intemalization and digestion of the PrP 8C complex.
  • Agostoni A., et al. Activation of complement and kinin systems after thrombolytic therapy in patients with acute myocardial infarction: a comparison between streptokinase and recombinant tissue-type plasminogen activator.
  • DAF decay-accelerating factor
  • nemaviruses 29. Narang, H.K. Evidence that single-stranded DNA wrapped around the tubulofilamentus particles termed "nemaviruses" is the genome of the scrapie vims. Res. Virology 1998 Vol. 149:375-382

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Rheumatology (AREA)
  • Rehabilitation Therapy (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La présente invention concerne des procédés et des compositions conçus pour détecter des substances cibles à analyser, telles que des protéines et des acides nucléiques, dans de multiples compartiments cellulaires. Des modes de réalisation préférés concernent la mise en oeuvre d'essais à médiation par complément et de traitements à médiation par complément chez l'être humain et l'animal. La présente invention concerne également des procédés et des compositions conçus pour surveiller plusieurs stades de maladie et d'infection.
PCT/US2002/016302 2001-05-22 2002-05-22 Essais a mediation par complement pour des procedes in vivo et in vitro WO2003063763A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP02806678A EP1506314A4 (fr) 2001-05-22 2002-05-22 Essais a mediation par complement pour des procedes in vivo et in vitro
JP2003563459A JP2005516198A (ja) 2001-05-22 2002-05-22 ｉｎｖｉｖｏおよびｉｎｖｉｔｒｏでの方法に関する補体媒介性アッセイ
AU2002365902A AU2002365902A1 (en) 2001-05-22 2002-05-22 Complement mediated assays for in vivo and in vitro methods
CA002447892A CA2447892A1 (fr) 2001-05-22 2002-05-22 Essais a mediation par complement pour des procedes in vivo et in vitro

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US29261601P 2001-05-22 2001-05-22
US60/292,616 2001-05-22
US29732101P 2001-06-11 2001-06-11
US60/297,321 2001-06-11
US32402901P 2001-09-21 2001-09-21
US60/324,029 2001-09-21

Publications (2)

Publication Number Publication Date
WO2003063763A2 true WO2003063763A2 (fr) 2003-08-07
WO2003063763A3 WO2003063763A3 (fr) 2004-12-09

Family

ID=27670579

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/016302 WO2003063763A2 (fr) 2001-05-22 2002-05-22 Essais a mediation par complement pour des procedes in vivo et in vitro

Country Status (5)

Country Link
EP (1) EP1506314A4 (fr)
JP (1) JP2005516198A (fr)
AU (1) AU2002365902A1 (fr)
CA (1) CA2447892A1 (fr)
WO (1) WO2003063763A2 (fr)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001056456A2 (fr) * 2000-02-02 2001-08-09 Cygene, Inc. Procedes et compositions permettant de detecter une maladie

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JUHL ET AL: 'A monoclonal antibody-cobra venom factor conjugate increases the tumor-specific uptake of a 99mTC-labeled anti-carcinoembryonic antigen antibody by a two-step approach' CANCER RESEARCH vol. 55, no. SUPPL., December 1995, pages 5749S - 5755S, XP000872898 *
See also references of EP1506314A2 *

Also Published As

Publication number Publication date
EP1506314A4 (fr) 2005-08-24
AU2002365902A1 (en) 2003-09-02
WO2003063763A3 (fr) 2004-12-09
EP1506314A2 (fr) 2005-02-16
JP2005516198A (ja) 2005-06-02
CA2447892A1 (fr) 2003-08-07

Similar Documents

Publication Publication Date Title
US20020004586A1 (en) Prion-binding activity in serum and proteins
JP4842478B2 (ja) 生物学的試料における非通常伝達因子株によって引起こされる亜急性伝達性海綿状脳症の診断方法
US7807386B2 (en) Peptides for discrimination of prions
WO2006033974A2 (fr) Detection d'agregats de proteines au moyen d'un dosage elisa homologue
EP1435521B1 (fr) Détéction et diagnostic de l'encephalopathie spongiforme transmissible
WO2003063763A2 (fr) Essais a mediation par complement pour des procedes in vivo et in vitro
WO2002000713A1 (fr) Activite de liaison au prion dans le serum et dans le plasma designes comme plasminogene et fibrinogene
EP1921451A2 (fr) Analyses induites par complément pour procédés in vivo et in vitro
JP2009529130A (ja) 病原性プリオン類の検出試験法
WO1996027131A1 (fr) Detection d'anticorps anti-adn impliquant la reconnaissance et la fixation de sequences d'adn telomeres
EP2085404B1 (fr) Peptides pour la discrimination des prions
US8663943B2 (en) Antibodies for discrimination of prions
WO2009040508A2 (fr) Procédés
EP1445615A1 (fr) Procede pour discrimination des prions infectieux et non infectieux
US20050282238A1 (en) High-sensitivity chemiluminescent ELISA prion detection method
EP2553465A1 (fr) Procédé de détection d'une dégradation de tissus conduisant à une inflammation
KR20070006757A (ko) Ｃｊｄ 프리온 시험

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2447892

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2003563459

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2002806678

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 2002806678

Country of ref document: EP